The measurement of KRAS G12 mutants using multiplexed SRM and Ion Mobility Mass Spectrometry.
There is a considerable clinical demand to determine key mutations in genes involved with cancer which necessitates the deployment of highly specific and robust analytical methods. Multiplex LC/SRM assays offer the ability to achieve quantitation down to levels expected to be present in clinical samples. Ion mobility mass spectrometry (IM-MS) assays can provide increased peak capacity and hence separation in an extremely short timeframe, and in addition provide physicochemical data regarding an analytes collision cross section which can be used in conjunction with an ion's m/z value to increase detection specificity. For LC/SRM, unlabelled peptides and corresponding stable-isotope labelled standards and injected were spiked into digested human plasma and analysed using nanoUPLC coupled to a triple quadrupole mass spectrometer to enable the generation of analyte specific calibration lines. Synthetic unlabelled peptides were infused into a Synapt G2 mass spectrometer for separation by TWIMS and TW CCSN2 values derived from comparison with previously generated TW CCSN2 calibration values. Linear calibration lines (0.125 to 25 fmol/μL) were established for each of the KRAS peptides. UPLC separated the peptides and hence enabled them to be split into different retention time functions/windows. This separation enabled detection of three or four transitions for each light and heavy peptide with at least 10 points per peak for accurate quantitation. All six KRAS G12 peptides were separated by IM-MS, enabling precise TW CCSN2 values to be determined. Although some of the G12 peptides chromatographically co-eluted, all the peptides were distinguished by the m/z, retention time and/or drift time (DT). This study advocates that LC/SRM and IM-MS could both be used to identify single amino acid substitutions in KRAS as an alternative to commonly used methods such as circulating tumour DNA (ctDNA) analysis.